Does vitamin D prevent you from catching COVID-19?
The short answer is no — not in a way that matters for most people. The most rigorous evidence comes from randomized controlled trials (RCTs), the gold standard of medical research. In one large RCT of 228 healthcare workers, those given vitamin D2 had a 50.5% infection rate, nearly identical to the 52.4% rate in the untreated group — a statistically meaningless difference [1]. Another major double-blind trial with 1,747 newly diagnosed COVID-19 patients found that giving high-dose vitamin D3 (up to 9,600 IU daily) did not reduce healthcare visits or hospitalizations compared to placebo [2].
A 2024 meta-analysis of 16 studies did find a protective effect against infection in RCTs (40% lower odds), but this was driven by smaller, lower-quality trials [7]. When you look only at the largest, most reliable studies, the benefit disappears. The Cochrane review, which is considered the most authoritative summary of medical evidence, concluded there is currently insufficient evidence to determine whether vitamin D prevents COVID-19 [12].
Can vitamin D help if you already have COVID-19?
This is where the picture gets more nuanced. For people who are vitamin D deficient, supplementation may reduce the risk of severe disease and death. A 2025 meta-analysis of nine RCTs in deficient patients found that vitamin D supplementation reduced the risk of death during follow-up by 24% (risk ratio 0.76) [4]. However, this benefit did not hold up for other measures like 28-day mortality, need for mechanical ventilation, or ICU admission — those differences were not statistically significant [4].
Older adults may benefit most. A 2022 study of hospitalized patients averaging 78 years old found that those who had taken vitamin D supplements in the three months before infection had 57% lower odds of developing severe COVID-19 and 66% lower odds of needing ICU care [6]. This aligns with a large population study of 4.6 million people, which showed that patients who achieved blood vitamin D levels above 30 ng/mL through supplementation had lower risks of severe COVID-19 and death [9].
The evidence on mortality is mixed. Some meta-analyses show a reduction in death [5], while others find no effect [3][11]. The difference likely comes down to who is studied: benefits are clearest in people who start with low vitamin D levels, not in those with adequate levels.
Who should consider taking vitamin D for COVID-19?
The evidence points to a targeted approach: vitamin D helps those who are deficient, not everyone. In a study of US veterans, those with blood levels below 19 ng/mL saw the largest reduction in infection risk after supplementation — a 28% lower risk with vitamin D2 and 20% lower with vitamin D3 [8]. Black veterans, who are more likely to be deficient, got greater benefit than White veterans [8].
For hospitalized COVID-19 patients, experts recommend checking vitamin D levels and correcting deficiency if found. A 2025 review suggests aiming for blood levels above 30 ng/mL, with maintenance doses of 2,000-3,000 IU per day [10]. But the same review warns against blanket supplementation for everyone, noting that high-dose supplements on the market can cause vitamin D excess, which carries its own risks [13].
The bottom line: if you are generally healthy and not deficient, there is no strong evidence that vitamin D supplements will protect you from COVID-19. If you are older, have darker skin, or are known to be deficient, supplementation may reduce your risk of severe illness — but it is not a substitute for vaccination or other proven preventive measures.
About These Sources
This answer is built on 13 peer-reviewed studies — published from 2021 to 2026, 5 from 2024 or later, 7 in Q1 journals, collectively cited 527 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 66 papers retrieved from a database of over 500 million.
Sources used in this answer
Randomized trial of influence of vitamin D on the prevention and improvement of symptomatic COVID-19
In a randomized trial of 228 healthcare workers, vitamin D2 supplementation did not reduce COVID-19 infection rates (50.5% vs 52.4%) or symptom severity, though adequate vitamin D levels showed a non-significant trend toward prevention.
A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial.
In a large double-blind RCT of 1,747 newly diagnosed COVID-19 patients, high-dose vitamin D3 (up to 9,600 IU/day) did not significantly reduce healthcare utilization or COVID-19 outcomes compared to placebo.
Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis
A meta-analysis of 3 studies (532 hospitalized patients) found vitamin D supplementation reduced ICU requirement (64% lower odds) but had no significant effect on mortality.
Vitamin D supplementation for managing COVID-19 in patients with vitamin D deficiency: a systematic review and meta-analysis of randomised controlled trials.
A 2025 meta-analysis of 9 RCTs in vitamin D-deficient COVID-19 patients found supplementation reduced mortality during follow-up by 24%, but did not improve 28-day mortality, mechanical ventilation need, or ICU admission.
Vitamin D supplementation and Covid‐19 outcomes: A systematic review, meta‐analysis and meta‐regression
A meta-analysis of 11 studies (22,265 patients) found vitamin D supplementation was associated with reductions in ICU admission (73% lower odds), mechanical ventilation (66% lower odds), and mortality (63% lower odds), with age influencing the association.
Vitamin D and COVID-19 Severity in Hospitalized Older Patients: Potential Benefit of Prehospital Vitamin D Supplementation
In a retrospective study of 228 older hospitalized patients (average age 78), pre-hospital vitamin D supplementation was associated with 57% lower odds of severe COVID-19 and 66% lower odds of ICU admission.
Preventive Vitamin D Supplementation and Risk for COVID-19 Infection: A Systematic Review and Meta-Analysis
A 2024 meta-analysis of 16 studies found vitamin D supplementation had a protective effect against COVID-19 incidence in RCTs (40% lower odds) and analytical studies (41% lower odds), and reduced ICU admission (68% lower odds).
Association between vitamin D supplementation and COVID-19 infection and mortality
In a study of US veterans, vitamin D2 and D3 supplementation was associated with 28% and 20% lower COVID-19 infection risk, respectively, and 33% lower mortality with D3, with greatest benefit in those with blood levels below 19 ng/mL.
Vitamin D supplementation and COVID-19 risk: a population-based, cohort study
In a population-based study of 4.6 million people, cholecalciferol supplementation achieving blood levels ≥30 ng/mL was associated with lower risk of SARS-CoV-2 infection, severe COVID-19, and COVID-19 mortality.
The relation of vitamin D deficiency and COVID-19
A narrative review recommends vitamin D supplementation for COVID-19 prevention at 400-1000 IU/day for adults, and for hospitalized patients, aiming for blood levels >30 ng/mL with maintenance doses of 2000-3000 IU/day.
The Association between Vitamin D Deficiency and Developing COVID-19 Related Serious Illnesses—A Systematic Review and Meta-Analysis
A meta-analysis found vitamin D deficiency was significantly more common in COVID-19 patients than healthy controls (2.65 times higher odds), but supplementation did not significantly reduce mortality.
Vitamin D supplementation for the treatment of COVID-19: a living systematic review
A Cochrane living systematic review of 3 RCTs (356 participants) concluded there is insufficient evidence to determine the benefits and harms of vitamin D supplementation as a treatment for COVID-19.
COVID-19 pandemic and vitamin D: rising trends in status and in daily amounts of vitamin D provided by supplements
A study in Dublin found that during the COVID-19 pandemic, average vitamin D blood levels increased and the dose of new vitamin D supplements rose, but also noted an increased risk of vitamin D excess, recommending targeted rather than blanket supplementation.
